Plus, Tessellate BIO, led by former Big Pharma execs, comes out of stealth.
Lumen Bioscience gets $16M to advance C. diff therapy:
The Department of Defense
awarded $16.2 million
to the Seattle-based company, which is developing an oral drug to treat and prevent infections with
C. difficile
. It plans to start enrolling 375 patients in a late-stage trial for LMN-201 by the end of the year.
Flashpoint’s $10M:
Flashpoint Therapeutics on Tuesday announced a $10 million seed round, led by Riyadh-based Beta Lab. The funds are expected to help advance the company’s first cancer therapy and select a second candidate. Flashpoint’s platform is based on work out of Chad Mirkin’s lab at Northwestern University’s International Institute for Nanotechnology.